Patent Application
20090220533
The present invention is within the field of the determination of antigenic peptides, capable of stimulating T-helper responses (Th1).
T-helper lymphocytes (Th1) perform various important functions in immunity to pathogens. In first place, the induction of an effective effector immune response, either a humoral response or a cytotoxic cellular response, requires the activation of Th1, and more specifically of specific subpopulations of Th1 (Th1, Th2, Th0). Secondly, the Th1 can also act directly as effector cells, an activity mediated by direct cell contact or by the release of lymphokines (IFN-γ, TNF-α, etc.). Therefore, the stimulation of T-helper (Th) responses constitutes a very relevant aspect for the development of vaccines.
It is well known that to achieve a stimulating effect, the Th1 recognize, through specific receptors (CTR) situated on its surface, complexes formed between Class II MHC molecules and antigenic peptides. These peptides which bind to the Class II MHC molecules, also known as Th epitopes or Th antigenic determinants (Thd), typically have sizes between 11 and 22 amino acids, and more frequently between 13 and 16 amino acids.
In recent years, vaccines based on epitopes have awoken considerable interest as a possible tool in the development of new vaccines and immunotherapeutic strategies. A careful selection of epitopes for B and T cells should permit directing the immune responses towards conserved epitopes of certain pathogens, characterized by great sequence variability (e.g. malaria, hepatitis C virus, HIV, etc.).
Furthermore, vaccines based on epitopes offer the opportunity of including chimeric Thd which have been manufactured to modulate their stimulating potency, either increasing their binding capacity with the MHC molecules of the main histocompatibility complex, or modifying the contact residues with the TCR receptors of T cells, or modifying both characteristics. Due to the chimeric nature of these peptides, there are very few probabilities that their sequence is contained on own antigens, for which reason, if after their use, their antibodies were induced against the peptides, there would be very little probability of inducing undesired responses against own antigens.
The prediction and selection of the appropriate epitopes comes up, however, against an important obstacle: the great number of polymorphisms existing between the MHC molecules, which very particularly affect the binding regions to the epitope and Th1 recognition. This polymorphism is produced as a result of the polygenic character of MHC histocompatibility and the great number of allelic variants existing for each one of these genetic loci. Thus, for example, human Class II MHC comprises 3 pairs of genes (each pair with its α and β chain), called HLA-DR, HLA-DP and HLA-DQ, which give rise to 4 basic types of Class II HLA molecules. A general review can be found in the manual: Immunobiology—The immune system in health and disease; Janeway C A Jr and Travers P Eds.; Current Biology Ltd/Garland Publishing Inc., London, 1997 3rd Ed. This polymorphism gives rise to the expression of many different MHC molecules, each of them with different ranges of specificity for the binding of epitopes (MHC restriction).
Although the specific allele polymorphic residues which surround the binding groove to the epitope give the MHC molecule the capacity to bind to a certain set of peptides, there are several cases wherein a same peptide can bind to one more than one allelic form of the MHC molecule. This has particularly been verified for HLA-DR molecules, where various allelic forms HLA-DR may recognise similar peptide motifs, at the same time as it has been verified that certain peptides are recognized by different HLA-DR molecules. This has led to the concept that certain peptides could represent promiscuous or universal epitopes.
Thus, the use of different algorithms has permitted defining various motifs useful for the selection of epitopes, having identified some universal epitopes recognized by a good number of isoforms of the HLA molecules, and more particularly of HLA-DR (WO95/07707; Alexander J et al. Immunity, 1994, 1:751-761; WO98/32456).
This last type of more promiscuous peptide may be of great use in inducing humoral and cellular responses in a great diversity of healthy individuals, which would avoid having to choose special peptides depending on the HLA-DR of said individuals.
Although a set of these promiscuous PADRE peptides is already available (Alexander J et al. Immunity, 1994, 1:751-761), it continues to be of interest to identify new promiscuous chimeric peptides. This is due to despite that fact that all these peptides share being recognized by several HLA-DR, some peptides may be better than others for a specific HLA-DR. Consequently, it would be of great use to have a wider battery of promiscuous peptides to thus better cover the induction of responses compared with the totality of the HLA-DR. Furthermore, it is also desirable to identify peptides which are bound and can be recognized in the context of the other HLA-DP and HLA-DQ isotopes. This would permit generating vaccines and immotherapeutic products for a wider spectrum of persons.
With the purpose of identifying new chimeric peptides which had the potential of binding strongly to different HLA-DR molecules, and in consequence, being capable of providing help for the induction of antibodies and also cytotoxic T responses, a set of peptides of 13 amino acids was synthesized. Formulas or templates of sequences were established for this, devised taking a motif of 8 amino acids described by the inventors themselves as starting reference (Borrás-Cuesta F. et al.; Specific and general HLA-DR binding motifs: comparison algorithms; Human Immunol., 2000; 61:266-278).
Firstly, peptides were synthesized whose sequence adapted to the formula:
I) a1-a2-Y-R-a5-M-a7-R-a9-R-A-A-A;
where Y is Tyr; R is Arg; M is Met; A is Ala; a1 is Phe or Tyr; a2 is Lys or Arg; a5, a7 and a9 are any of the 20 natural amino acids.
In all cases, a tyrosine was used as primary anchor in the third residue (first residue of the aforementioned motif). Furthermore, to reach the typical length of 13 amino acids in most of the Thd (Chicz R. M. et al.; Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size; Nature, 1992; 358: 764-768), three alanines were added to the nucleus of 8 amino acids at their C-terminal end and another two amino acids at their N-terminal end: an aromatic amino acid (phenylalanine or tyrosine) in the first residue and an amino acid with positive charge (lysine or arginine) in the second residue. The use of phenylalanine or tyrosine in the first residue provides an additional anchoring point.
Furthermore, the amino acids which occupy positions 4, 6, 8 and 10 of the peptides were fixed in said formula.
Other formulas for the synthesis and evaluation of peptides were established from the first formula, wherein the possibility was left open of varying two of the four amino acids fixed in aforementioned positions 4, 6, 8 and 10. The formulas tested were the following:
II) a1-a2-Y-R-a5-M-a7-a8-a9-a10-A-A-A;
III) a1-a2-Y-a4-a5-M-a7-a8-a9-R-A-A-A;
IV) a1-a2-Y-R-a5-a6-a7-a8-a9-R-A-A-A;
where Y is Tyr; R is Arg; M is Met; A is Ala; a1 is Phe or Tyr; a2 is Lys or Arg; a4 is any of the 20 natural amino acids other than Arg; a5, a7 and a9 are any of the 20 natural amino acids; a6 is any of the 20 natural amino acids other than Met; a8 is any of the 20 natural amino acids other than Arg; and a10 is any of the 20 natural amino acids other than Arg.
A peptide of the following sequence was also synthesized:
V) SEQ. ID. NO: 21,
wherein the amino acids were varied in 3 of the initially fixed positions, keeping methionine in position 6.
For comparative purposes, short peptides of 8 and 9 amino acids were also synthesized which also had tyrosine as primary anchor and in the majority of the remaining positions of the nucleus, amino acids that favour binding to HLA-DR.
Once synthesized, its capacity of binding strongly to different allelic forms of the HLA-DR, molecule was evaluated, with the result that the majority were capable of strongly binding to at least one of the allelic forms.
A general sequence was obtained from the above. Thus, in a first embodiment, the present invention relates to a chimeric peptide with capacity to bind to at least one allelic form of the HLA-DR molecule, characterized in that its sequence of amino acids adapts to a formula selected from:
a) a1-a2-Y-a4-a5-a6-a7-a8-a9-a10-A-A-A; and
b) SEQ. ID. NO: 21;
where Y is Tyr; A is Ala; a1 is Phe or Tyr; a2 is Lys or Arg; a4 is Arg, except when a6 and a10 are Met and Arg, respectively, where a4 can be any of the natural amino acids; a5, a7 and a9 are any of the 20 natural amino acids; a6 is Met except when a4 and a10 are Arg, case wherein a6 is any of the natural amino acids; a8 is Arg, except when a4 is Arg, Tyr or His, a6 is Met or Val and a10 is Met, His or Arg, case wherein a8 is any of the natural amino acids; and a10 is Arg, except when a4 is Arg or His and a6 is Met, case wherein a10 is any of the natural amino acids.
Therefore, a second aspect of the present invention relates to a chimeric peptide with capacity to bind to at least one allelic form of the HLA-DR molecule whose sequence of amino acids adapts to one of the previously defined formulas I), II), III), and IV). Hereinafter, we refer to this as “chimeric peptide of the invention” or “peptide of the invention”. In a particular embodiment said HLA-DR allelic form corresponds to the HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8 or HLA-DR11 serotype.
In a particular embodiment, the chimeric peptide of the invention strongly binds to at least 2 allelic forms of HLA-DR of different serotype, and preferably 3, 4, 5, 6 or even 7 of these allelic forms.
In some cases, the chimeric peptide of the invention can also bind to other isotopes of Class II HLA molecules, for example HLA-DP or HLA-DQ. In a particular embodiment, they also bind to some allelic forms of HLA-DQ.
In a preferred embodiment, the chimeric peptide of the invention behaves as a Th antigenic epitope or determinant (Thd). The terms Th or Thd determinant are indiscriminately used and mean that said peptide, bound to the HLA molecule, is recognized by Th lymphocytes, and is capable of inducing the activation of said Th lymphocytes or T-helper cells (Th response). This activation is evidenced by its capacity for inducing the proliferation of Th lymphocytes and to induce the production of specific lymphokines of these Th lymphocytes, such as IL-4, IFN-γ or TNF-α. The Th response induced can be a Th1 or Th2 response, or a mixed Th0 response. This capacity of acting as Thd is possible in the context of at least one of the forms of HLA-DR, HLA-DP or HLA-DQ indicated.
Preferably, the chimeric peptide of the invention is also capable of inducing an effective humoral or cytotoxic T response. In an embodiment said response is a CT response.
In a particular embodiment, the chimeric peptide of the invention is a peptide of sequence SEQ. ID. NO: 1, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 20 or SEQ. ID. NO: 22.
The chimeric peptides of the invention can be obtained by conventional methods, for example, by solid phase chemical synthesis techniques; purification by high performance liquid chromatography (HPLC); and, if desired, they can be analysed using conventional techniques, for example, by sequencing or mass spectrometry, amino acid analysis, nuclear magnetic resonance, etc. Alternatively, the peptides of the invention can also be obtained via recombinant DNA technology.
The chimeric peptides of the invention could be used for administration to a subject (a man, a woman or any other mammal) with immunoprophylactic or immunotherapeutic purposes. Therefore, in another aspect, the invention also relates to a pharmaceutical composition which contains a chimeric peptide of the invention (or a plurality thereof) and a pharmaceutically acceptable excipient.
In a particular embodiment, a chimeric peptide of the invention (or a plurality thereof) can be administered in an immunostimulating combination together with another or other immunogens different from the chimeric peptides of the invention. This combination can be presented in the form of a single pharmaceutical composition or separate pharmaceutical compositions for combined administration, by a simultaneous or sequential administration, by the same administration route or by different routes. Thus, the present invention also relates to a pharmaceutical composition characterized in that it comprises a chimeric peptide of the invention and another immunogen.
The term “immunogen” relates to a molecule which is cable of inducing a specific immunological response to said immunogen (humoral: production of antibodies; or cellular: activation of Th lymphocytes, activation of CT lymphocytes, etc.). Due to its chemical nature, the immunogen can be almost any molecule: for example, polypeptides, lipopeptides, oligosaccharides, polysaccharides, nucleic acids, lipids or other chemical compounds as drugs. By its origin, said immunogen may come, for example, from a pathogen (virus, bacteria, fungus, parasite, etc.), of a tumour cell, of synthesis (drugs or other synthesis compounds) or of any other origin (for example, allergens). In some cases, said immunogen is a proteic antigenic determinant, for example a Th antigenic determinant or a CT antigenic determinant.
In a more particular embodiment, the pharmaceutical composition of the invention contains a cytotoxic T determinant (CTd) and a chimeric peptide of the invention (or a plurality thereof) which acts as T-helper determinant (Thd).
When the pharmaceutical composition contains a chimeric peptide of the invention and another or other immunogens, these may be presented as separate molecules or in conjugated form, for example, by covalent bonds. The conjugation may be performed by various conventional methods which are described, for example, in: “The current protocols in protein chemistry”, published by John Wiley & Sons (periodically updated; Last updated 1 May 2005); “Immobilized affinity ligand Techniques”, G T Hermanson, A K Mallia and P K Smith, Academic Press, Inc. San Diego, Calif., 1992; EP0876398; among others.
The pharmaceutical composition which comprises a chimeric peptide of the invention may additionally contain, carriers, excipients and other pharmaceutically acceptable ingredients.
Still in another additional aspect, the invention relates to the use of a chimeric peptide of the invention (or a plurality thereof) in the preparation of an immunostimulating pharmaceutical composition. This pharmaceutical composition may be used to induce a specific immune response to an immunogen administered in combination with a chimeric peptide, within the same composition or in separate compositions as has been previously described. In this way, the chimeric peptide of the invention is used to induce a Th response (activation of Th lymphocytes) in a subject administered the pharmaceutical composition. Said response can be a Th 1 or Th2 response or a mixed Th0 response.
In a particular embodiment, this Th response cooperates in the activation of B lymphocytes, so that the pharmaceutical composition with the chimeric peptide is useful for inducing a humoral immune response.
In another embodiment, the Th response collaborates in the activation of CT lymphocytes, so that the pharmaceutical composition is useful for inducing a cytotoxic T cell response (CT).
Additionally, the immunostimulating pharmaceutical composition with the chimeric peptide of the invention may have other uses, such as, for example, the in vitro treatment or pre-conditioning of dendritic cells with therapeutic purposes.
In consequence, the immunostimulating pharmaceutical composition which contains a chimeric peptide of the invention is useful for the treatment and prophylaxis of an infectious (bacterial, viral, fungal or parasitic), tumoral or allergic disease.
The immunostimulating pharmaceutical composition of the invention can be applied to any animal or human subject: e.g. mammals (human or otherwise), birds and similar. For this, any suitable route of administration can be used in accordance with the known conventional methods of the state of the art. A review of the different pharmaceutical forms of administration of drugs and excipients necessary for their production can be found, for example, in “Tecnología farmacéutica”, by J. L. Vila Jato, 1997 Vols I and II, Ed. Synthesis, Madrid; or in “Handbook of pharmaceutical manufacturing formulations”, by S. K. Niazi, 2004 Vols I a VI, CRC Press, Boca Raton. In a particular embodiment, the pharmaceutical composition is administered by parenteral route (e.g. intravenous, subcutaneous, intramuscular, intraperitoneal), transdermal, mucosal or similar.
The invention also provides a therapeutic and/or prophylactic method which includes administering a pharmaceutical composition to a subject which includes a chimeric peptide of the invention (or a plurality thereof). This method permits activating the Th lymphocytes in said subject inducing a Th response which collaborates well in the stimulation of a humoral response for the production of antibodies, or in the stimulation of a cytotoxic response by activation of specific CT lymphocytes against an immunogen. Said method can be a method for the therapeutic or prophylactic treatment of an infectious disease (bacterial, viral, fungal or parasitic), tumoral or allergic disease.
The peptides for the assays of binding to the HLA molecules and induction of T-helper (Th) and cytotoxic T (CT) responses were manually synthesized by the Merrifield solid phase method, using the Fmoc technology [(Merrifield R B; Solid phase synthesis. I. J Am Chem Soc, 1963; 85:2149); (Atherton E Procedures for solid phase synthesis. J Chem Soc Perkin Trans, 1989; 1:538)]. Both the peptides to test and the peptides used as control were synthesized using this same method (Table 1).
Biotinylated peptides were also used for some assays: the HA (306-320) (APKYVKQNTLKLATG) peptide of the hemaglutinine of the Flu virus and p45. These peptides were synthesized manually and were conjugated with biotin (EZ-Link Sulfo-NHS-LC-Biotin; Pierce Biotechnology, Inc, Rockford, USA). For this, once the peptide synthesis had concluded, this remained bound to the resin and 10 washes were performed with a DMF-water mixture (7.5:2.5) to prepare the resin to this new solvent. Biotin dissolved in this solvent was added, in proportion (1:1) with the milliequivalents of the initial resin. The mixture was allowed to react for one and a half hours. Next, the resin was washed 20 times with DMF, and the reaction process was repeated up to 3 times. To check that the peptide was biotinylated, the Kaiser test was performed (Kaiser, 1970; Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970; 34:595-598). The resin was cut, liophilised and analysed by HPLC as in the previous section. [(Merrifield R B; Solid phase synthesis. I. J Am Chem Soc, 1963; 85:2149); (Atherton E Procedures for solid phase synthesis. J Chem Soc Perkin Trans, 1989; 1:538)].
The PADRE peptide was synthesized for comparative purposes. This is a peptide similar to another previously developed (Alexander J et al. Immunity, 1994, 1:751-761) with the purpose of inducing T-helper responses in a wide variety of HLA-DA molecules. This PADRE peptide was differentiated from the previously described peptide in that it was synthesized with the amino acid phenylalanine instead of the original cyclohexylalanine.
The binding of the peptides was measured as described by Busch et al. (Busch R, Rothbard J: Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol, 1990; 144:1849).
In the experiments of the present invention, the following lines of B lymphocytes were used transformed by Epstein-Barr virus (EBV-BLCL), each one of them homozygotic for different HLA-DA molecules:
All the cell lines were obtained from the European Collection of Animal Cell Cultures (ECACC, PHLS, Salisbury, UK).
Briefly, B lymphocytes with different HLA-DA molecules (at 2.5×105 cells/well) were coincubated throughout the night with biotinylated HA(306-320) (10 μM) and non-biotinylated HA(306-320) (100 μM) on the one side, or with biotinylated HA(306-320) (10 μM) and the peptide to test (100 μM) on the other. The incubation was carried out in complete MC medium (RPMI 1640 with 10% calf foetal serum, 2 mM of glutamine, 100 U/ml of penicillin, 100 μg/ml of streptomycin, 5×10−5 M of 2 β-mercaptoethanol, and 0.5% (v/v) of sodium pyruvate). On the next day, 2 washes were carried with 200 μl of FACS medium (2.5% PBS of calf foetal serum); 5 μg/ml of streptavidin-fluorescein (Pierce) in 100 μl of FACS medium and they were incubated at 4° C. for 30 minutes. Next, 2 washes were performed and the cells were resuspended in 200 μl of FACS medium.
The fluorescence of the cell surface was measured by flow cytometry in a FACScan analyser (Becton Dickinson Immunocytochemistry System, Mountain, USA). The mean fluorescence of 5,000 labelled cells was measured. A fluorescence signal was obtained proportional to the number of HLA-DR molecules exposed on the outside of the cell.
The following formula was used to quantify the binding capacity of each peptide (% Bindingpeptide):
% Bindingpeptide=100×((Fpeptide−Fblnk)/(Fctrl.blot−Fblnk))
where Fpeptide is the fluorescence measured by the peptide to test Fblnk is the fluorescence measured without added peptide (blank); and Fctrl.blot is the fluorescence measured for the biotinylated control peptide [HA(306-320)].
In this way, the binding percentage was calculated using the non-biotinylated control peptide [HA(306-320)] as test peptide (% Bindingctrl):
% Bindingctrl=100×((Fctrl.nobiot−Fblnk)/(Fctrl.biot.−Fblnk))
HA (306-320) was used as reference control, instead of the CPKYVKQNTLKLATG peptide as previously described (Rothbard J B; Degenerate binding of immunogenic peptides. Int Immunol 1990; 2:443-451), in order to prevent the formation of potential disulfur bridges via cysteine-NH2 terminal.
The relative binding percentages (% BR) was also calculated according to the following formula:
% BR=100×(% Bindingpeptide/% Bindingctrl)
where % Bindingpeptide is the binding percentage of the peptide to test; and where % Bindingctrl is the binding percentage of the non-biotinylated control peptide of the HA(306-320) control peptide.
All the assays were performed in triplicate. The variation in the fluorescence intensities of the triplicates was always in the 5-10% range.
In this was it was possible to obtain an evaluation of the binding capacity of the different peptides to HLA-DA1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR11 molecules, expressed in terms relative to the binding of the non-biotinylated HA peptide: APKYVKQNTLKLATG (
The p45, p61 and p62 peptides exhibited a binding capacity comparable to or even greater than the PADRE peptide tested.
p45 was fairly insoluble. In order to better characterize its binding capacity, and to reject a possible toxic effect of the peptide, it was decided to perform some complementary tests using biotinylated p45.
In first place, tests were performed for binding to HLA-DR in the different cell lines, incubated with biotinylated p45 at different concentrations. To avoid the possible crystallization of the peptide, this was solubilized with the aid of a sonicator. The fluorescence of the cell surface was measured by flow cytometry in a FACScan analyser as seen in example 2, although there was no competition with the non-biotinylated p45 peptide.
In second place, the HLA-DR4 cell line was incubated in the presence of the biotinylated P45 peptides and antibodies selected due to their specificity to HLA-DR, HLA-DP, HLA-DQ and Class I HLA respectively (
In a 96-well plate with U-shaped bottom, the HLA-DR4 cell line was seeded (already defined); (2×105 per well), also adding biotinylated P45 peptides (10 μM), alone or together with supernatant of the hybridomas: L243 anti-HLA-DR (ATCC Ref: HB-55), or W6/32 anti-Class I (ATCC Ref: HB-95) or the antibodies 33.1 anti-HLA-DQ or anti-HLA-DP B7/21, which were provided by Dr. Ghislaine Sterkers. All were diluted to (1/500) in a final volume of 100 μl of RPMI with 2.5% FBS. The next day, 2 washes were performed with 200 μl of FACS medium, 5 μg/ml of streptavidin-fluorescein conjugate (Pierce) in 100 μl of FACS, and they were they were incubated at 4° C. for 30 minutes. Next, 2 washes were performed and the cells were resuspended in 200 μl of FACS medium. The fluorescence of the cell surface was measured by flow cytometry in a FACScan analyser. The mean fluorescence of 5,000 labelled cells was measured. A fluorescence signal was obtained proportional to the number of HLA-DR molecules exposed on the outside of the cell.
The following formula was used to quantify the decrease in binding capacity on adding the antibodies:
% Inhibition=100×((Fp45+aHLA−Fblnk)/(Fp45−Fblnk))
where Fblnk is the fluorescence measured when the cells were cultured without adding peptide or antibodies (blank), Fp45 is the fluorescence measured when it was incubated with the biotinylated P45 peptides alone, and Fp45+aHLA is the fluorescence measured when it was measured with the biotinylated p45 together with the corresponding HLA antibodies.
All the assays were performed in triplicate. The variation in the fluorescence intensities of the triplicates was always in the 5-10% range.
As can be seen in
In this way, these tests were repeated on the HLA-DR1, HLA-DR3, HLA-DR7, HLA-DR8, HLA-DR11 cell lines. The inhibition percentages obtained are set down in Table 2. As can be observed, when the cells were incubated with biotinylated p45 in the presence of anti-HLA-DR or anti-HLA-DQ, a strong inhibition occurs in all cases, which indicates that the biotinylated p45 has a high capacity of binding to HLA-DR and to HLA-DQ in all the cell lines.
The biotinylated P45 peptides bound to HLA-DR1, although non-biotinylated p45 does not bind in detectable manner to this HLA molecule (see
In order to check if the synthesized peptides had the capacity of inducing Th responses in vivo, transgenic mice were immunized for the HLA-DR4 molecule with some of the peptide which had demonstrated binding capacity with various HLA-DA molecules. For this, p37, p45, p61 and p62 were chosen, also using the PADRE peptide as control. All these peptides showed binding capacity to several HLA-DA molecules, whilst they showed different degrees of binding to HLA-DR4. The Th inducing capacity was evaluated measuring the peptide's capacity of inducing cell proliferation and of inducing the production of IFN-γ and IL4 in lymphocytes extracted from the immunized mice.
HLA-DR4 transgenic female mice obtained from Taconic were used (Germantown, N.Y., USA), which were maintained in conditions free from pathogens and treated following the standards of our institution.
For the induction of Th responses, groups of 3 mice were immunized (4-6 weeks old) with 200 μg of a 1:1 emulsion of complete Freund's adjuvant and saline solution which contained 50 nanomoles of the corresponding peptide. The immunized animals were sacrificed two weeks after immunization and the popliteal, inguinal and periaortic lymph nodes were extracted. The nodes were homogenized with a syringe and were washed three times in a washing medium (RPMI 1640 medium) at 4° C. Next, 5×107 cells/ml were pulsed in MC during 2 hours at 37° C. with 10 μM of the corresponding peptide.
Then, they were centrifuged and resuspended and 2×106 cells/ml were cultured in a volume of 2 ml, in a 24 well plate, in an oven at 37° C. with 5% CO2. Seven days later, the cells were washed and 5×105 T cells were cultured per well with 2×105 cells of syngenic spleen per well, treated with mitomicyn-C, in the absence or presence of the corresponding antigen. 50 μl of the supernatant were collected to measure IFN-γ and IL-4 as in the previous section. The cell proliferation was measured.
After 48 hours in culture, the cells were pulsed with 0.5 μCi of tritiated thymidine during 18 hours, they were harvested and the incorporation of thymidine was determined in a scintillation counter (Top-count; Packard, Meridan, Conn., USA).
The quantities of IFN-γ and IL-4 were measured using commercial ELISA (OPTEIA Mouse IFN-γ Set, Pharmingen, San Diego, USA and OPTEIA Mouse IL-4 Set, Pharmingen, San Diego, USA) in accordance with the manufacturer's instructions. The results were expressed as pg/ml using a standard curve of known quantities of cytokines.
The results (
In order to study the peptides' capacity to collaborate in the induction of CT effector responses, mice (transgenic for HLA-DR4) were immunized with p37, p45, p61, p62 or with the PADRE control peptide, together with the SIINFEKL peptide [OVA(257-264)]. SIINFEKL is a cytotoxic T determinant (CTd) which binds to the class I H-2 Kb molecule.
To induce cytotoxic response, two mice of 4 to 6 weeks of age were immunized subcutaneously with 200 μl of a 1:1 emulsion of incomplete Freund's adjuvant and saline solution which contained 50 nanomoles of the corresponding peptide.
The animals were sacrificed between 10 and 12 days after immunization to extract the popliteal, inguinal and periaortic lymph nodes. These nodes were homogenized with a syringe to obtain a cell suspension and were washed three times in RPMI 1640.
The cells obtained were incubated with the cytotoxic determinant SIINFEKL (10 μM) during 2 hours at 37° C., they were washed twice and were cultured in 24-well plates at a concentration of 7.5×106 cells/well. Two days later, 2.5 U/ml of IL-2 were added to the culture and five days later the cytotoxic activity was measured, following the methodology described by Brunner (Brunner K T; “Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs”; Immunology, 1968; 14:181).
The cytotoxic activity was assayed by the measurement of the release of 51Cr from the target cells, previously labelled. The target cells used were timon cells (H-2b) El-4 (Reference ATCC: TIB-39). For their labelling, 50 μCi of 51CrO4Na2 were added for each 106 target cells in a final volume of 100 μl and they were incubated in the absence or presence of SIINFEKL peptide (at a concentration of 10 μM) during 2 hours at 37° C. After three washes in RPMI 1640, they were resuspended in 1 ml of MC. The assay was performed in 96-well plates with U-shaped bottoms. The effector cells and the target cells were added separately (3000 per well). Different proportions of effector cells were assayed with respect to the target cells, in serial dilutions (100, 33, 11 and 3). Each assay was performed in triplicate. The final volume of each well was 200 μl.
The plates were incubated during 4 hours at 37° C. Then, 50 μl of supernatant was extracted from each well and the radioactivity was counted in a scintillation counter.
The percentage of specific lysis was calculated according to the following formula:
% Specific lysis=100×((cpmexperimental−cpmspontaneous)/(cpmmaximum−cpmspontaneous)
The maximum lysis was determined measuring the cpm (counts per minute) of 3000 target cells incubated with 5% Triton X-100 and the spontaneous lysis from cells incubated in the absence of effector cells.
The percentage of lysis indicated corresponds to the net lysis: value of the lysis against the immunized animal cells to which the lysis substrate observed against the animals cells without immunization.
The results, represented in
In order to determine if the p37, p45 and p62 peptides could be recognized by the human Th lymphocytes of a varied population, experiments were performed with mononuclear cells of peripheral blood extracted from the umbilical cords from donors.
The extracted cells were purified using the Ficoll method (Noble P B, Cutts J H, Carroll, K K; Ficoll flotation for the separation of blood leukocyte types; Blood, 1968; 31:66-73). Once purified, the cells (3×106 cells/ml) were pulsed for two hours with 10 μM of the peptide under study. The cells pulsed were washed and plated (105 cells/well) in flat-bottomed 96-well plates. On days 3 and 7, IL-2 was added. Fifteen days later, the cells of each well were subdivided in two, to contrast them respectively to cells (105 cells/well) treated with mitomicyn C, with or without each one of the p37, p45, p62 or PADRE peptides. After two days, 50 μl of each supernatant was collected and was kept frozen at −20° C. until the time at which the quantity of IFN-γ was quantified by ELISA. The cells were pulsed on the third day, during 18 hours with 0.5 μCi of tritiated thymidine. They were then harvested and the incorporation of thymidine was measured in a scintillation counter.
First, the DNA was extracted from mononuclear cells of peripheral blood from each donor. The QIAmp DNA Mini Kit (Qiagen, Valencia, USA) was used and the protocol indicated by the manufacture was followed.
For the embodiment of the typing from extracted DNA, the Inno-Lipa HLA-DRB1 Plus kit (Innogenetics, Ghent, Belgium) was used, following the protocol indicated by the manufacturer.
Table 3 indicates the number of positive wells for each peptide and donor. Only those wells that showed a stimulation index equal to or greater than 3 were considered positive. The stimulation index (SI) was expressed as the quotient between the counts per minute between the well with peptide and the well without peptide.
| Number | Date | Country | Kind |
|---|---|---|---|
| P2005503169 | Dec 2005 | ES | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/ES2006/000695 | 12/19/2006 | WO | 00 | 9/25/2008 |
